Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/49747
Title: Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population
Authors: Saloranta, Carola
Guitard, Christiane
Pecher, Eckhard
De Pablos-Velasco, Pedro 
Lahti, Kaj
Brunel, Patrick
Groop, Leif
Keywords: Type-2 Diabetes-Mellitus
Postchallenge Hyperglycemia
Cardiovascular-Disease
Fasting Glucose
Life-Style, et al
Issue Date: 2002
Publisher: 0149-5992
Journal: Diabetes Care 
Abstract: OBJECTIVE - The purpose of this study was to evaluate the metabolic effectiveness, safety and tolerability of nateglinide in subjects with impaired glucose tolerance (IGT) and to identify a dose appropriate for use in a diabetes prevention study.RESEARCH DESIGN AND METHODS - This multicenter, double-blind, randomized, parallel-group, fixed-dose study of 8 weeks' duration was performed in a total of 288 subjects with IGT using a 2:2:2:1 randomization. Subjects received nateglinide (30, 60, and 120 mg) or placebo before each main meal. Metabolic effectiveness was assessed during a standardized meal challenge performed before and after the 8-week treatment. All adverse events (AEs) were recorded, and confirmed hypoglycemia was defined as symptoms accompanied by a self-monitoring of blood glucose measurement less than or equal to3.3 mmol/l (plasma glucose less than or equal to 3.7 mmol/l).RESULTS - Nateglinide elicited a dose-related increase of insulin and a decrease of glucose during standardized meal challenges, with the predominant effect on early insulin release, leading to a substantial reduction in peak plasma glucose levels. Nateglinide was well tolerated, and symptoms of hypoglycemia were the only treatment-emergent AEs. Confirmed hypoglycemia occurred in 28 subjects receiving nateglinide (30 mg, 0 [0%] 60 mg, 5 [6.6%] 120 mg, 23 [26.7%]) and in 1 (2.3%) subject receiving placebo.CONCLUSIONS - Nateglinide was safe and effective in reducing postprandial hyperglycemia in subjects with IGT. Preprandial doses of 30 or 60 mg nateglinide would be appropriate to use for longer-term studies to determine whether a rapid-onset, rapidly reversible, insulinotropic agent can delay or prevent the development of type 2 diabetes.
URI: http://hdl.handle.net/10553/49747
ISSN: 0149-5992
DOI: 10.2337/diacare.25.12.2141
Source: Diabetes Care[ISSN 0149-5992],v. 25, p. 2141-2146
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

36
checked on Jul 25, 2021

WEB OF SCIENCETM
Citations

30
checked on Jul 25, 2021

Page view(s)

13
checked on Jul 25, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.